BRIEF published on 05/28/2024 at 13:05, 5 months 24 days ago CureVac Announces Dosing of First Participant in Phase 2 Influenza Study GSK MRNA Technology Phase 2 Study CureVac Influenza Vaccine
PRESS RELEASE published on 05/28/2024 at 13:00, 5 months 24 days ago CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK CureVac initiates Phase 2 study in collaboration with GSK for seasonal influenza vaccine, targeting improved immune responses against influenza B strain GSK Vaccine Development Phase 2 Study CureVac Seasonal Influenza
BRIEF published on 05/23/2024 at 13:05, 5 months 29 days ago CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update Financial Results Business Update Q1 2024 CureVac FDA Fast Track
PRESS RELEASE published on 05/23/2024 at 13:00, 5 months 29 days ago CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update CureVac announces financial results for Q1 2024, reports €300.2 million cash position and updates on organizational restructuring and patent litigations Financial Results Cash Position CureVac Patent Litigation Organizational Redesign
BRIEF published on 04/24/2024 at 13:11, 6 months 27 days ago CureVac Announces 2023 Financial Results and Strategic Business Updates MRNA Technology CureVac Pharmaceutical Collaborations Oncology Vaccines Prophylactic Vaccines
BRIEF published on 04/24/2024 at 13:08, 6 months 27 days ago CureVac Begins Combined Phase 1/2 Study for Avian Influenza H5N1 Vaccine with GSK GSK CureVac Phase 1/2 Study Influenza H5N1 MRNA Vaccine
PRESS RELEASE published on 04/24/2024 at 13:06, 6 months 27 days ago CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update CureVac announces financial results for the fourth quarter and full-year 2023, along with business updates, organizational redesign, collaborations, and appointments Financial Results Business Update Collaborations CureVac Organizational Redesign
BRIEF published on 04/24/2024 at 13:05, 6 months 27 days ago CureVac Appoints Thaminda Ramanayake as New Chief Business Officer Business Development Biopharmaceutical MRNA Technology Corporate Strategy CureVac
PRESS RELEASE published on 04/24/2024 at 13:03, 6 months 27 days ago CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK CureVac initiates combined Phase 1/2 study with GSK for H5N1 avian influenza vaccine candidate, leveraging mRNA technology for pandemic preparedness MRNA Technology CureVac Phase 1/2 Study GSK Collaboration H5N1 Avian Influenza
PRESS RELEASE published on 04/24/2024 at 13:00, 6 months 27 days ago CureVac Appoints Thaminda Ramanayake as New Chief Business Officer CureVac appoints Thaminda Ramanayake as Chief Business Officer, bringing extensive biopharma experience. Ramanayake to enhance strategic partnerships and accelerate mRNA therapies Biopharma CureVac Thaminda Ramanayake Chief Business Officer MRNA Therapies
Published on 11/22/2024 at 09:00, 1 hour 28 minutes ago Industrial Software Company mlean Celebrates 10 Years of Continuous Improvement
Published on 11/22/2024 at 00:00, 10 hours 28 minutes ago Gratomic Announces Company and Operational Update
Published on 11/21/2024 at 22:05, 12 hours 23 minutes ago Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Published on 11/21/2024 at 21:50, 12 hours 38 minutes ago Seventy Ninth Resources Announces Successful First Reconnaissance at McKellar Copper-Zinc and Enable Gold Projects
Published on 11/21/2024 at 20:15, 14 hours 13 minutes ago Woodland Park Zoo Awarded Transformative Grant to Advance Empathy for Animals
Published on 11/22/2024 at 09:45, 43 minutes ago The GSMA – China Unicom Open Gateway Global Use Case Innovation Challenge has begun!
Published on 11/22/2024 at 09:23, 1 hour 5 minutes ago Turkiye Garanti Bankasi A.S.: Announcement regarding issuance of subordinated notes
Published on 11/22/2024 at 09:06, 1 hour 22 minutes ago Original-Research: NFON AG (von NuWays AG): Buy
Published on 11/21/2024 at 06:58, 1 day 3 hours ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 1 day 15 hours ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 1 day 16 hours ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 1 day 16 hours ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 2 days 2 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
